Immunology Journal Publishes Data For Adamis' COVID-19 Candidate

Adamis Pharmaceuticals Corporation ADMP has announced Tempol data publication in the peer-reviewed journal Clinical Immunology.
Tempol is a novel antioxidant that inhibits both activated T cell and APC (Antigen Presenting Cell) derived cytokines in-vitro from COVID-19 patients.
The studies conducted at the Human Immune Monitoring Center at Stanford University investigated the effects of Tempol on immune cells from COVID-19 patients.
The authors conclude, "Preincubation of immune cells with Tempol resulted in a significant (P<0.05) decrease in multiple T cell and APC-derived cytokines from both cells of COVID-19 and uninfected donors.
Dr. Holden Maecker, Director of the Human Monitoring Center at Stanford University, commented: "These results suggest that Tempol has strong, broad in-vitro anti-cytokine activity.
In animal models, Tempol has been shown to decrease proinflammatory cytokines (cytokine storm) and lung inflammation.
In addition, Tempol works as an antioxidant and has demonstrated decreasing harmful reactive oxygen species and platelet aggregation.
Related: NIH Sees Promise in Tempol for COVID-19.
Price Action: ADMP shares are up 0.15% at $1.09 during the market session on the last check Tuesday.